FACTORS ASSOCIATED WITH BIOLOGIC TREATMENT DE-ESCALATION IN PATIENTS WITH CROHN'S DISEASE

被引：0
|
作者：
Lien, P. W. [1 ]
Lee, T. A. [2 ]
机构：
[1] Univ Illinois, Chicago, IL USA
[2] Univ Illinois, Coll Pharm, Chicago, IL USA
来源：
VALUE IN HEALTH | 2024年 / 27卷 / 06期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
CO117
引用
收藏
页码：S38 / S38
页数：1
相关论文
共 50 条
  • [1] BIOLOGIC TREATMENT DE-ESCALATION IN PATIENTS WITH CROHN'S DISEASE IS COMMON IN THE UNITED STATES
    Lien, Pei-Wen
    Kochar, Bharati
    Kim, Kibum
    Lee, Todd
    Walton, Surrey
    Winn, Aaron
    INFLAMMATORY BOWEL DISEASES, 2025, 31 : S54 - S54
  • [2] Treatment de-escalation in Crohn's disease
    Brierley, Rob
    LANCET GASTROENTEROLOGY & HEPATOLOGY, 2022, 7 (04): : 290 - 290
  • [3] Treatment de-escalation in Crohn's disease
    Louis, Edouard
    LANCET GASTROENTEROLOGY & HEPATOLOGY, 2023, 8 (05): : 401 - 401
  • [4] De-escalation of Biologic Treatment in Inflammatory Bowel Disease: A Comprehensive Review
    Gisbert, Javier P.
    Chaparro, Maria
    JOURNAL OF CROHNS & COLITIS, 2024, 18 (04) : 642 - 658
  • [5] Treatment escalation and de-escalation decisions in Crohn's disease: Delphi consensus recommendations from Japan, 2021
    Nakase, Hiroshi
    Esaki, Motohiro
    Hirai, Fumihito
    Kobayashi, Taku
    Matsuoka, Katsuyoshi
    Matsuura, Minoru
    Naganuma, Makoto
    Saruta, Masayuki
    Tsuchiya, Kiichiro
    Uchino, Motoi
    Watanabe, Kenji
    Hisamatsu, Tadakazu
    TRADE Consensus Grp
    JOURNAL OF GASTROENTEROLOGY, 2023, 58 (04) : 313 - 345
  • [6] Treatment escalation and de-escalation decisions in Crohn’s disease: Delphi consensus recommendations from Japan, 2021
    Hiroshi Nakase
    Motohiro Esaki
    Fumihito Hirai
    Taku Kobayashi
    Katsuyoshi Matsuoka
    Minoru Matsuura
    Makoto Naganuma
    Masayuki Saruta
    Kiichiro Tsuchiya
    Motoi Uchino
    Kenji Watanabe
    Tadakazu Hisamatsu
    Journal of Gastroenterology, 2023, 58 : 313 - 345
  • [7] TREATMENT DE-ESCALATION IN CROHN'S DISEASE PATIENTS IN REMISSION UNDER INFLIXIMAB AND IMMUNOSUPPRESSANT THERAPY: THE SPARE TRIAL
    Louis, Edouard
    Resche-Rigon, Matthieu
    Laharie, David
    Ding, Nik
    Irving, Peter
    Lamb, Christopher
    Pollok, Richard
    Colombel, Jean-Frederic
    Hertervig, Erik
    Satsangi, Jack
    GUT, 2022, 71 : A27 - A27
  • [8] INFLIXIMAB DE-ESCALATION IN PATIENTS WITH CROHN'S DISEASE IN CLINICAL REMISSION IS SAFE AND WELL TOLERATED
    Allegretti, Jessica R.
    McClure, Emma L.
    Marcus, Jenna
    Norton, Beth Ann
    Hamilton, Matthew
    Winter, Rachel
    De Silva, Punyanganie
    Friedman, Sonia
    Korzenik, Joshua R.
    GASTROENTEROLOGY, 2020, 158 (06) : S461 - S461
  • [9] Factors Associated With Ustekinumab Dose Escalation in Patients With Crohn's Disease
    Njie, Cheikh
    Dalal, Rahul S.
    Allegretti, Jessica R.
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2020, 115 : S368 - S368
  • [10] Infliximab De-escalation in Patients With Crohn's Disease in Clinical Remission Is Safe and Well-tolerated
    Allegretti, Jessica R.
    Canakis, Andrew
    McClure, Emma
    Marcus, Jenna
    Norton, Beth-Ann
    Hamilton, Matthew J.
    Winter, Rachel W.
    De Silva, Punyanganie S.
    Friedman, Sonia
    Korzenik, Joshua R.
    INFLAMMATORY BOWEL DISEASES, 2021, 27 (12) : 2031 - 2033
12345